Dystrogen Therapeutics is pioneering a novel approach to treating Duchenne Muscular Dystrophy (DMD) through its Dystrophin Expressing Chimeric (DEC) cell therapy. This innovative therapy is designed to be a universal solution for all patients with DMD, regardless of their specific genetic mutations. Unlike traditional methods that involve genetic manipulation, DEC therapy utilizes engineered chimeric cells created by fusing normal donor myoblasts with the myoblasts of DMD-affected patients. This process results in DEC cells that express higher levels of dystrophin and CD56, closely resembling healthy myoblasts while maintaining the immune profile of the recipient. This unique characteristic allows DEC cells to evade the patient’s immune system, eliminating the need for immunosuppression and enabling the possibility of redosing without sensitization.

The clinical development of DEC therapy is currently underway, with a focus on safety and efficacy in a structured clinical trial involving a small cohort of patients. The trial is designed to assess various endpoints, including muscle strength, mobility, and cardiac function over an extended follow-up period. By leveraging the advantages of chimeric cell engineering, Dystrogen Therapeutics aims to revolutionize the treatment landscape for DMD, providing a potential therapeutic option that is both effective and safe for patients suffering from this debilitating condition.

United States

Dystrogen Therapeutics is a clinical stage chimeric cell therapy company focusing on rare diseases. The company is currently testing DEC therapy for Duchenne Muscular Dystrophy. 

Dystrogen Therapeutics

Company Details